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Abstract
Oral squamous cell carcinoma (OSCC) is an aggressive disease accounting for more than
260,000 cancer cases diagnosed and 128,000 deaths worldwide. A large majority of cancer
deaths result from cancers that have metastasized beyond the primary tumor. The relation-
ship between genetic changes and clinical outcome can reflect the biological events that
promote cancer’s aggressive behavior, and these can serve as molecular markers for
improved patient management and survival. To this end, epithelial-mesenchymal transition
(EMT) is a major process that promotes tumor invasion and metastasis, making EMT-
related proteins attractive diagnostic biomarkers and therapeutic targets. In this study, we
used immunohistochemistry to study the expression of a panel of transcription factors
(TWIST1, SNAI1/2, ZEB1 and ZEB2) and other genes intimately related to EMT (CDH1 and
LAMC2) at the invasive tumor front of OSCC tissues. The association between the expres-
sion of these proteins and clinico-pathological parameters were examined with Pearson
Chi-square and correlation with survival was analyzed using Kaplan Meier analysis. Our
results demonstrate that there was a significant differential expression of CDH1, LAMC2,
SNAI1/2 and TWIST1 between OSCC and normal oral mucosa (NOM). Specifically, CDH1
loss was significantly associated with Broder’s grading, while diffused LAMC2 was similarly
associated with non-cohesive pattern of invasion. Notably, co-expression of TWIST1 and
ZEB2 in OSCC was significantly associated with poorer overall survival, particularly in
patients without detectable lymph node metastasis. This study demonstrates that EMT-
related proteins are differentially expressed in OSCC and that the co-expression of TWIST1
and ZEB2 could be of clinical value in identifying patients with poor survival for appropriate
patient management.
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Introduction
Despite commendable advancements in the prevention, detection and treatment of cancer, oral
squamous cell carcinoma (OSCC) still remains a significant global health burden, accounting
for over 260,000 diagnosed cases and 128,000 deaths worldwide [1]. Cancer metastasis which
arises when cancer cells spread from the primary tumor to form new tumors in distant organs
is the primary cause of death in most cancer patients. This process involves changes in tumor
tissue architecture that promote invasion and metastasis and is regulated through a mechanism
known as epithelial-mesenchymal transition (EMT) [2]. The activation of EMT facilitates can-
cer epithelial cells to undergo dedifferentiation to a mesenchymal phenotype and in the process
gain a metastatic capability that allows these cells to invade through the basement membrane
and migrate to regional lymph node or distant organs [2]. The emerging roles of some key
EMT-related proteins in cancer progression and their close correlation with clinico-pathologi-
cal parameters make them attractive targets for developing diagnostic biomarkers and thera-
pies [3]. However, with the complexity of signaling networks involved in EMT, an in depth
understanding of which of the related proteins are important in this process would hold value
in translating this information for clinical benefit.
While the initiation of EMT is a complex process involving many complex pathways [2],
the loss of cell adhesion among epithelial cells is a key event, defined by the down-regulation of
E-cadherin (CDH1). Expression of CDH1 is regulated by transcription factors including
SNAI1, SNAI2, ZEB1, ZEB2 and TWIST1 which act either directly or indirectly on the CDH1
promoter [2, 4]. These transcription factors form signaling networks that could initiate and
sustain the mesenchymal phenotypes of tumor cells [3], and therefore the expression of these
proteins could define EMT occurrence in a tumor setting. Most notably, LAMC2, the γ2 chain
of Laminin 332, has been shown to be involved in tumor migration and invasion processes [5,
6]. Furthermore, overexpression of LAMC2 in OSCC is also associated with loss of cell polarity
[7], likely suggesting a role in tumor spread.
EMT occurrence demonstrated by the expression of EMT-associated proteins as described
above has been reported for many different cancer types including head and neck cancer [3, 4,
8]. Some of these studies broadly focused on interrogating the invasive front of the tumor, an
area where tumor cells have been reported to have the highest malignant potential [9–11]. In
these studies, CDH1 loss and overexpression of SNAI1, TWIST1 and LAMC2 were observed at
the invasive front of the tumors, particularly in single or cords of tumor cells detaching from
the tumor mass [7, 12–23]. Additionally, loss of CDH1, and overexpression of SNAI1 and
LAMC2 at the invasive front have been associated with metastasis and worse prognosis in oral,
esophageal and lung cancer [15, 19–21]. While the expression of these EMT drivers have been
well studied in many cancers, in OSCC this process has largely been defined by CDH1 switch-
ing (from E-cadherin to N-cadherin), and information regarding expression patterns of other
EMT markers including the EMT transcription factors in OSCC is limited. Furthermore, in
light of regional metastasis being the single most important prognostic factor for OSCC [24],
there is a need to determine the nature of the transcription factors that may be involved in can-
cer progression and how they may impact clinical outcome.
In this study, using immunohistochemistry, we sought to understand the expression pattern
of EMT-related markers (CDH1, LAMC2, SNAI1/2, TWIST1, ZEB1 and ZEB2) at the invasive
front of OSCC archival specimens. From our observation, we demonstrated a significant differ-
ence in the expression of several key proteins (CDH1, LAMC2, SNAI1/2 and TWIST1)
between OSCC and non-malignant oral mucosa (NOM) tissues. Specifically, CDH1 loss at the
invasive front was associated with Broder’s grading and diffused LAMC2 was associated with
non-cohesive pattern of invasion. Notably, co-expression of transcription factors, TWIST1 and
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ZEB2, was associated with a poorer patient overall survival, particularly in cohorts without
detectable lymph node metastasis, likely suggesting a clinical utility in identifying patients with
poor survival for appropriate patient management.
Materials and Methods
Archival OSCC tumor tissues and construction of tissue microarray
(TMA)
In this retrospective study, 148 formalin-fixed paraffin-embedded (FFPE) tissues blocks
including histopathologically confirmed OSCC (n = 87) and NOM tissues were included
(n = 61; consisting of denture hyperplasia, impacted third molar gingival tissue and matching
normal mucosa tissue adjacent to the tumor). OSCC tissues included in this study were diag-
nosed between 2003 and 2011 at University of Malaya and the Institute for Medical Research
(IMR) and followed-up up till July 2013. Primary surgical lesions with identifiable invasive
tumor front were included, and clinical information (i.e. tumor stage, tumor size, lymph node
metastasis, pattern of invasion (POI), Broder’s grading and overall survival) from these patients
were obtained from the Malaysian Oral Cancer Database & Tissue Bank System (MOCDTBS)
at the Oral Cancer Research and Coordinating Centre (OCRCC), University of Malaya, Malay-
sia [25], and the IMR (Table 1). Tissues from metastatic and recurrent lesions were excluded
from this study. Written informed consent was obtained from the participants for their clinical
records to be used in this study and all patient information was anonymized and de-identified
prior to analysis. This study was approved by the Institutional Review Board, of the Faculty of
Dentistry, University of Malaya (Ethical Clearance number: DF OP1109/0084(L)).
Three representative areas of invasive tumor fronts in OSCC specimens and two representa-
tive areas of the NOM tissues were identified by board certified pathologists (AR, TGK, RBZ
and LSH) for the construction of the tissue microarray (TMA). Tissue cores of 1.0 mm diame-
ter were extracted from the identified invasive tumor front areas using MiniCore 2 and TMA
designer 2 (Alphelys, France). Each core was then re-embedded into a recipient paraffin block
in an asymmetric grid-like arrangement [26]. The TMAs were then sectioned at 4 μm for
hematoxylin and eosin (H&E) or immunohistochemical (IHC) staining.
Selection of candidate EMT-related markers and immunohistochemical
staining
The occurrence of EMT has been associated with the loss of CDH1, and overexpression of pro-
teins including LAMC2 and EMT transcription factors SNAI1, SNAI2, TWIST1, ZEB1 and
ZEB2 [3, 4, 7, 22, 27, 28]. The expressions of these proteins were examined by immunohisto-
chemical staining (IHC).
IHC staining was performed according to manufacturer’s protocols for DakoCytomation
REAL EnVision Detection System-HRP or the Universal Biotinylated Link LSAB System-HRP
(Dako, Denmark) as previously described [29]. Information on the use of antibodies against
the EMT-related markers studied (SNAI1/2, TWIST1, ZEB1, and ZEB2) is summarized in S1
Table. FFPE tissues from breast, colorectal, cervical and ovarian cancers were used as positive
controls in these experiments as suggested on the data sheet for each of the antibodies used
(S1A–S1H Fig). Ten random whole tissue sections were also immuno-stained against these
EMT-related markers to confirm that similar staining patterns and intensities were observed in
these whole tissue sections and their respective TMA cores.
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Evaluation of immunohistochemical staining
Each core was considered to be suitable for evaluation if it contained epithelial cells (tumor and
normal). Only the immunohistochemical staining of the epithelial cells were graded, and for
those samples with no epithelial cells in all of the corresponding three tissue cores, evaluation
was not performed. The evaluation of the immunohistochemical staining was carried out by
three pathologists (AR, TGK and LSH), who were essentially blind to all histopathological and
clinical data and any discrepancies were discussed to reach a consensus agreement to a defini-
tive score.
Table 1. Demographics and clinico-pathological characteristics of patients.
Tissue type Total samples (n = 148) (%)
Non-malignant 61 41.2
Denture hyperplasia 7 11.5
Impacted third molar gingival 20 32.8
Adjacent normal 34 55.7
OSCC 87 58.8
Variables OSCC (n = 87) (%)
Gender Male 34 39.1
Female 53 60.9
Age Range 28 to 86
Mean 59.1
Tumor Site Cheek 33 37.9
Tongue 33 37.9
Gum 9 10.3
Others (lip and palate) 12 13.8
Tumor Size Tis 1 1.1
T1 & T2 39 44.8
T3 & T4 47 54.0
Node Stage Nx 2 2.3
N0 47 54.0
N1, N2, N3 38 43.7
pTNM Stage Carcinoma in situ 1 1.1
I & II (early) 28 32.2
III & IV (late) 58 66.7
Pattern of Cohesive 21 24.1
Invasion Non-cohesive 66 75.9
Broders' Grading Well differentiated 40 46.0
Moderately/Poorly differentiated 42 48.3
N/A 5 5.7
Treatment Surgery alone 18 20.7
Surgery plus chemotherapy and/or radiotherapy 44 50.6
N/A 25 28.7
Overall survival Range (months) 1 to 90
Median 20
Abbreviations: OSCC, oral squamous cell carcinoma; n, number of specimens; N/A, not available.
doi:10.1371/journal.pone.0134045.t001
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As CDH1 expression was observed in both membrane and cytoplasm of epithelial cells,
only membranous staining was evaluated, as only the loss CDH1 expression at this location is
indicative of EMT occurrence [30] and is predominantly evaluated to determine the prognostic
significance of CDH1 [12, 21, 31, 32]. CDH1 staining was also categorized into uniformly posi-
tive, uniformly negative and heterogeneous as previously reported [33]. Uniformly positive
CDH1 expression refers to expression of membranous CDH1 in all layers of the epithelium
while heterogeneous CDH1 expression indicates gradual loss of membranous CDH1 in tumor
cells [33]. Also, cytoplasmic LAMC2 staining was categorized into diffused (cytoplasmic
LAMC2 staining in all layers of cells), peripheral (LAMC2 staining at peripheral layer but not
at the center of the tumor island) and negative (no cytoplasmic expression and/or expression
at the basement membrane lining the normal epithelium) as reported by others [7]. The inten-
sity of nuclear expression was evaluated for EMT transcription factors, where 0 = negative
staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining [34–36]. The extent of
positive staining was not taken into account for the overall analyses largely due to the percent-
age derived from TMA tissue cores would only represent a small proportion of the invasive
front area and not the whole tissue section. Overall, the scores were consistent in all the cores
from each specimen. However, where there were differences among the three tissue cores, the
highest intensity or worse pattern of staining (e.g. heterogeneous CDH1 and diffused LAMC2
staining) was taken. The evaluation scores of EMT transcription factors were further separated
into binary scores. For SNAI1/2, this separation was based on median intensity as described by
Galvan et al. [34]. The median of intensity score for SNAI1/2 in this study was 3, hence SNAI1/
2 scores were divided into 0, 1, 2 versus 3. Similarly, the median of intensity score for ZEB2 and
TWIST1 was computed to be 0, hence the scores were divided into negative (0) versus positive
(1, 2 and 3) as described by others [35, 36]. None of the samples expressed ZEB1, therefore,
binary score of ZEB1 could not be computed and statistical analyses could not be conducted
for ZEB1. The evaluation scores for CDH1 and LAMC2 were also further separated into binary
scores. CDH1 scores were divided into preserved (uniformly positive) and reduced (uniformly
negative/heterogeneous) while LAMC2 scores were divided into diffused and non-diffused
(negative/basement membrane/peripheral). The criteria for evaluation of all markers are sum-
marized in S1 Table.
Statistical analysis
Following the “Reporting Recommendations for Tumor Marker Prognostic Studies”
(REMARK) criteria closely, the minimum number of samples that are needed for this study
was determined using a sample size calculator computing for a two-sided chi-square analysis.
Using data from published studies, we demonstrated that the number of specimens included in
this study was adequate, as the minimum required number of normal and OSC tissues were 56
and 10 respectively, to achieve a statistical power of 80% and significant p value of 0.05 (S2
Table). Statistical analyses were performed using SPSS for Windows 16.0 (IBM Inc., New York,
USA). Pearson Chi-square test was performed to determine the statistical associations of the
expression of EMT-related markers with different tissue types (i.e. NOM and OSCC) and clin-
ico-pathological parameters (i.e. tumor stage, tumor size, node metastasis, pattern of invasion
(POI) and Broders’ grading). Kaplan-Meier survival analysis was used to correlate survival
rates with EMT-related proteins’ expressions, and the survival probability differences were
compared by the log-rank test. Cox regression multivariate analyses were also performed to
adjust for other factors that could influence the patient’s survival including tumor stage, pat-
tern of invasion and lymph node metastasis. Any missing values were omitted from the analy-
sis and a p-value<0.05 was considered to be statistically significant.
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Results
Demographics and clinico-pathological characteristics of OSCC patients
A total of 148 tissue samples including 87 OSCC and 61 NOM tissues were analyzed. The
demographics and clinico-pathological information on the OSCC patients are included in
Table 1. The follow-up survival data were available for 79/87 patients (90.8%) with the maxi-
mum follow-up period of 90 months and a mean and median survival of 26.7 and 20 months
respectively (Table 1).
EMT-related markers were differentially expressed in OSCC and NOM
tissues
Before investigating the expression of EMT-related markers in OSCC and NOM tissues, we
first sought to demonstrate that the staining pattern and intensity was broadly similar between
ten random whole tissue sections and their respective TMA cores extracted from these sections
(S2 Fig). On the TMA, an average of 129 (87.2%) tissue samples was deemed as interpretable
for analyses. Among all the 6 markers tested, the expression of CDH1, SNAI1/2, LAMC2 and
TWIST1, were noted to be differentially expressed between NOM and OSCC tissues (Fig 1;
Table 2). Reduced CDH1 was observed in 64.9% of OSCC tissues compared to 20.7% of NOM
tissues (p< 0.001; Table 2). The pattern of LAMC2 staining differed significantly in NOM and
OSCC tissues (Fig 1) where 98% of NOM tissues had non-diffused staining and 52.4% of the
OSCC had diffused staining (p< 0.001; Table 2).
Expression of SNAI1/2, ZEB2 and TWIST1 were observed in the nucleus as well as the cyto-
plasm of epithelial cells (Fig 1), however, only nuclear staining in normal and tumor epithelial
Fig 1. Representative immunostaining of EMT-relatedmarkers in non-malignant oral mucosa (Original magnification: 40X, 200X-Inset) and oral
squamous cell carcinoma tissues (OSCC; Original magnification: 200X).
doi:10.1371/journal.pone.0134045.g001
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cells was evaluated as these proteins are expected to regulate transcription [37]. SNAI1/2
nuclear expression was noted to be with stronger intensity in a large majority of OSCC tissues
(70.7%) compared to NOM tissues (34.7%; p< 0.001; Table 2). Despite the low prevalence,
TWIST1 expression was observed to be ~3 fold elevated in OSCC compared to NOM tissues
(p = 0.024; Table 2). Surprisingly, there was no significant difference in ZEB2 expression
between NOM and OSCC tissues (p = 0.144; Table 2). ZEB1 expression was not observed in
the nucleus of epithelial cells in NOM nor OSCC tissues although positive staining was
observed in the inflammatory cells, fibroblast, muscle and endothelial cells in the stromal com-
partments surrounding the tumor cells (Fig 1). To ensure that the absence of ZEB1 staining
was not due to quality of antibody used or experimental conditions, we thus stained for ZEB1
expression in breast cancer tissues that have been previously reported to express the protein
[38]. Positive nuclear ZEB1 expression was observed in epithelial cells of breast cancer tissues
(S1G Fig) confirming that NOM and OSCC inherently do not express this transcription factor.
Association of EMTmarkers expression with clinico-pathological
parameters
The association between the expressions of EMT-related markers with patients’ clinico-patho-
logical parameters was also examined. As the loss of CDH1 is now considered as one of the
Table 2. Differential expression of EMT-related proteins in non-malignant and OSCC tissues.
Tissue Type
CDH1
n Preserved (%) Reduced (%) p-value
NOM 58 46 (79.3) 12 (20.7)
OSCC 77 27 (35.1) 50 (64.9) <0.001*
Tissue Type
LAMC2
n Non-diffused (%) Diffused (%) p-value
NOM 49 48 (98.0) 1 (2.0)
OSCC 82 39 (47.6) 43 (52.4) <0.001*
Tissue Type
SNAI1/2
n Weak (%) Strong (%) p-value
NOM 49 32 (65.3) 17 (34.7)
OSCC 75 22 (29.3) 53 (70.7) <0.001*
Tissue Type
TWIST1
n Negative (%) Positive (%) p-value
NOM 51 46 (90.6) 5 (9.4)
OSCC 77 57 (74.0) 20 (26.0) 0.024*
Tissue Type
ZEB2
n Negative (%) Positive (%) p-value
NOM 53 31 (58.5) 22 (41.5)
OSCC 77 35 (45.5) 42 (54.5) 0.144
Tissue Type
ZEB1
n Negative (%) Positive (%) p-value
NOM 51 51 (100.0) 0 (0.0)
OSCC 73 73 (100.0) 0 (0.0) N/A
Abbreviations: NOM, non-malignant oral mucosa; OSCC, oral squamous cell carcinoma; n, number of specimens.
Data were analyzed by Pearson's Chi-Square test.
*p < 0.05.
doi:10.1371/journal.pone.0134045.t002
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hallmarks of EMT, we anticipated that reduced CDH1 expression would be observed in the
majority of poorly differentiated tumors. Indeed, CDH1 expression was significantly associated
with Broder’s grading where more than 80% of moderately/poorly differentiated tumors exhib-
ited reduced CDH1 expression (p = 0.003, Table 3). As SNAI1/2, TWIST1 and ZEB2 are
known to repress CDH1 expression, it is reasonable to expect to observe high expression levels
of these factors being similarly associated with parameters that are associated with CDH1 loss.
However, the expression of these transcription factors were not directly associated with the dif-
ferentiation status of tumor cells and consistent with this observation, significant association
between the expression of CDH1 and transcription factors was not demonstrated (S3 Table).
Pattern of invasion at the invasive front of tumors has been reported to be associated with
outcome where patients whose tumors were found to be non-cohesive had an increased risk
for metastasis and poorer survival [9, 39]. In this context, diffused LAMC2 expression was
associated with non-cohesive pattern of invasion (p = 0.011) and reduced CDH1 expression
was trending towards non-cohesive pattern of invasion (p = 0.064, Table 3). While EMT has
been widely associated with tumor metastasis and invasion in many tumors including OSCC
[12, 15, 34, 40–46], we did not observe any significant association between the EMT-related
markers examined in this study with nodal metastasis. Furthermore, association between
EMT-related markers with tumor stage and tumor size was also not observed.
Association of EMT-related markers expression with clinical outcome
The association between the expressions of EMT-related markers with patient survival was also
examined. None of the EMT-related markers, when analyzed alone, were significantly associ-
ated with overall survival in OSCC patients (S4 Table). However, as EMT networks are com-
plex and that these proteins could work collectively to drive cancer progression, we examined if
co-expression of these proteins could influence patient outcome. Amongst all the EMT-related
markers, patients with positive ZEB2 and TWIST1 expression were trending towards poorer
overall survival (p = 0.079 and p = 0.081 respectively; S3A and S3B Fig). With this observation,
survival analysis was further carried out to determine whether the co-expression of TWIST1
and ZEB2 was indicative of worse outcome in OSCC patients. Indeed, in combination, the
expression of these two markers were significantly associated with poorer overall survival in
OSCC patients with a two-year survival probability of 36% as compared to 62% in patients
without co-expression of these proteins (i.e. patients with expression of either marker and
patients who were negative for both markers; p = 0.025, Fig 2A). Furthermore, multivariate
analysis demonstrated that after correction with confounding factors, the co-expression
remains an independent prognostic factor and carries a 3.1-fold hazard ratio of poor overall
survival (95% CI: 1.314–7.138; p = 0.010; Table 4A). As lymph node metastasis is highly associ-
ated with poor prognosis [47], we determined the association between the co-expression of
TWIST1 and ZEB2 and patient survival in lymph node positive and negative patients sepa-
rately. The co-expression of TWIST1 and ZEB2 was significantly associated with poor survival
in patients without lymph node metastasis with a two-year survival probability of 57.1% as
compared to 78.3% in node-negative patients without the co-expression of these proteins
(p = 0.022, Fig 2B), but this was not observed in patients with positive node metastasis (Fig
2C). Multivariate analysis further demonstrated that the co-expression of TWIST1 and ZEB2
in node-negative patients remains independent prognostic factors with the hazard ratio of 3.8
(95% CI: (1.070–13.247); p = 0.039, Table 4B).
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Table 3. Association between expression of EMT-related proteins with clinico-pathological parameters.
Clinico-pathological parameters
CDH1
n Preserved (%) Reduced (%) p-value Odds Ratio 95% conﬁdence interval
Tumor Size
Tis, T1,T2 35 11 (31.4) 24 (68.5)
T3,T4 42 16 (38.1) 26 (61.9) 0.542 1.343 0.521–3.462
Node Metastasis
Negative 42 15 (35.7) 27 (64.3)
Positive 33 10 (30.3) 23 (69.7) 0.622 0.783 0.295–2.074
Tumor Stage
Early 24 7 (29.2) 17 (70.8)
Late 53 20 (37.7) 33 (62.3) 0.465 1.472 0.520–1.167
Pattern of Invasion
Cohesive 19 10 (52.6) 9 (47.4)
Non-cohesive 58 17 (29.3) 41 (70.7) 0.064 0.213 0.074–0.612
Broder's grading
Well 35 18 (51.4) 17 (48.6)
Moderate/poor 38 7 (18.4) 31 (81.6) 0.003* 0.373 0.129–1.081
Clinico-pathological parameters
LAMC2
n Non-diffused (%) Diffused (%) p-value Odds Ratio 95% conﬁdence interval
Tumor Size
Tis, T1,T2 40 20 (50.0) 20 (50.0)
T3,T4 42 19 (45.2) 23 (54.8) 0.666 1.211 0.508–2.884
Node Metastasis
Negative 47 24 (51.1) 23 (48.9)
Positive 33 13 (39.4) 20 (60.6) 0.303 1.605 0.651–3.959
Tumor Stage
Early 29 15 (51.7) 14 (48.3)
Late 53 24 (45.3) 29 (54.7) 0.577 1.295 0.523–3.207
Pattern of Invasion
Cohesive 21 15 (71.4) 6 (28.6)
Non-cohesive 61 24 (39.3) 37 (60.7) 0.011* 3.854* 1.313–11.317*
Broder's grading
Well 38 20 (52.6) 18 (47.4)
Moderate/poor 39 14 (35.9) 25 (64.1) 0.139 1.984 0.796–4.944
Clinico-pathological parameters
SNAI 1/2
n Weak (%) Strong (%) p-value Odds Ratio 95% conﬁdence interval
Tumor Size
Tis, T1,T2 38 9 (23.7) 29 (76.3)
T3,T4 37 13 (35.1) 24 (64.9) 0.276 0.573 0.209–1.569
Node Metastasis
Negative 42 12 (28.6) 30 (71.4)
Positive 31 8 (25.8) 23 (74.2) 0.793 1.150 0.404–3.275
Tumor Stage
Early 27 9 (33.3) 18 (66.7)
Late 48 13 (27.1) 35 (72.9) 0.568 1.346 0.484–3.742
Pattern of Invasion
Cohesive 20 9 (45.0) 11 (55.0)
Non-cohesive 55 13 (23.6) 42 (76.4) 0.072 2.643 0.899–7.772
Broder's grading
Well 32 13 (40.6) 19 (59.4)
Moderate/poor 38 8 (21.1) 30 (78.9) 0.075 2.566 0.896–7.344
Clinico-pathological parameters
TWIST1
n Negative (%) Positive (%) p-value Odds Ratio 95% conﬁdence interval
Tumor Size
Tis, T1,T2 39 28 (71.8) 11 (28.2)
T3,T4 38 29 (76.3) 9 (23.7) 0.651 0.790 0.284–2.196
Node Metastasis
Negative 43 33 (76.7) 10 (23.3)
Positive 32 24 (75.0) 8 (25.0) 0.861 1.100 0.378–3.201
Tumor Stage
Early 28 20 (71.4) 8 (28.6)
Late 49 37 (75.5) 12 (24.5) 0.694 0.811 0.285–2.310
Pattern of Invasion
Cohesive 21 15 (71.4) 6 (28.6)
Non-cohesive 56 42 (75.0) 14 (25.0) 0.75 0.833 0.271–2.563
Broder's grading
Well 34 23 (67.6) 11 (32.4)
Moderate/poor 38 30 (78.9) 8 (21.1) 0.277 0.558 0.193–1.610
(Continued)
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Discussion
EMT is an important process in the development of cancer and key features can be indicated
by the expression of specific proteins [2, 4]. EMT has been previously reported to occur at the
invasive tumor front [7, 12–23] suggesting that this process can likely contribute to the invasive
potential of tumor cells. While several studies have investigated the occurrence of EMT in
OSCC, these have largely focused only on the loss of CDH1 and the overexpression of LAMC2
[16, 48, 49]. Notably, other important EMT-related markers such as SNAI1, SNAI2, ZEB1,
ZEB2 and TWIST1 at the invasive tumor front were not thoroughly examined in these
reported studies. In this study, the expression of an extended panel of EMT related markers (i.
e. CDH1, LAMC2, SNAI1/2, ZEB1, ZEB2 and TWIST1) was examined in a large cohort of
tumor samples consisting of OSCC at the invasive tumor front of the tumor, in order to shed
light on important prognostic information [9–11]. Four of these EMT-related proteins (CDH1,
LAMC2, SNAI1/2 and TWIST1) were found to be differentially expressed between OSCC and
normal oral mucosal epithelium. Reduced expression of CDH1, a key protein of adherens junc-
tions anchoring oral epithelial cells to one another was observed. This is perhaps not surprising
as the loss of CDH1 expression results in the destabilization of adherens junctions and loss of
epithelial cell adhesion is an important event in tumorigenesis [50]. CDH1 loss has been fre-
quently reported in OSCC particularly at the invasive tumor front [16, 20, 21], and is well-rec-
ognized as one of the hallmarks of EMT.
Another indication that cells may have gained tumorigenic potential is the overexpression
of LAMC2. In this study, LAMC2 a basement membrane protein that maintains cell contact
integrity by promoting static adhesion and hemidesmosome formation [51], was found to be
overexpressed in the cytoplasm of OSCC cells. Notably, 2 distinct patterns of expression (i.e.
peripheral and diffused) have been previously reported in OSCC and these pattern of expres-
sion is associated with lymph node metastasis and poor prognosis [7, 22, 52]. In this study, the
majority of OSCC demonstrated diffused staining at the invasive front of the tumor, consistent
with its role in tumor invasion and migration [53].
One of the phenotypes of EMT is the change of cell morphology. This can be controlled by
the expression of Snail family of transcription factors which can impact cell shape and affect
cell adhesion, resulting in an increased invasive potential [54]. In this study, SNAI1/2 was
Table 3. (Continued)
Clinico-pathological parameters
ZEB2
n Negative (%) Positive (%) p-value Odds Ratio 95% conﬁdence interval
Tumor Size
Tis, T1,T2 37 15 (40.5) 22 (59.5)
T3,T4 40 20 (50.0) 20 (50.0) 0.405 0.682 0.276–1.682
Node Metastasis
Negative 43 20 (46.5) 23 (53.5)
Positive 32 14 (43.8) 18 (56.3) 0.812 1.118 0.445–2.806
Tumor Stage
Early 26 10 (38.5) 16 (61.5)
Late 51 25 (49.0) 26 (51.0) 0.379 0.650 0.248–1.701
Pattern of Invasion
Cohesive 18 8 (44.4) 10 (55.6)
Non-cohesive 59 27 (45.8) 32 (54.2) 0.922 0.948 0.328–2.741
Broder's grading
Well 33 14 (42.4) 19 (57.6)
Moderate/poor 40 20 (50.0) 20 (50.0) 0.518 0.737 0.291–1.863
Abbreviations: n, number of specimens.
Data were analyzed by Pearson's Chi-Square test.
*p < 0.05.
doi:10.1371/journal.pone.0134045.t003
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found to be significantly overexpressed, in greater than 70% of OSCC specimens. Similar to
our study, Wushou et al. reported that a high number of OSCC showed Snail expression
compared with normal epithelium [46]. Notably, Snail controls the expression of matrix metal-
loproteinases (MMPs) and other transcription factors (i.e. TWIST1, ZEB1, ZEB2) and there-
fore could be regarded as a master regulator of the EMT process [50]. In this study, TWIST1
was also found to be overexpressed in OSCC. Consistent with our observation, TWIST1 has
been reported to be over-expressed in several cancers including OSCC [45, 55]. In this
study, 26% OSCC showed overexpression of TWIST1 suggesting that TWIST1 could be an
important protein in a subset of OSCC patients, as also demonstrated by Sakamoto and col-
leagues [45].
Fig 2. Association of co-expression of TWIST1 and ZEB2 with survival. (a) OSCC patients with co-expression of TWIST1 and ZEB2 have poorer overall
survival compared to patients with no co-expression of these two proteins. Co-expression of TWIST1 and ZEB2 is significantly associated with overall
survival in node negative OSCC patients (b) but not in node positive OSCC patients (c).
doi:10.1371/journal.pone.0134045.g002
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The current understanding of the EMT process is that transcription factors including
SNAI1, SNAI2, ZEB1, ZEB2 and TWIST1 down-regulate CDH1 expression which subse-
quently results in the loss of cell adhesion and migration of tumor cells [4]. However, emerging
evidence suggests that transcription repression of CDH1 may not be a universal phenomenon
as an inverse association between the expression of CDH1 and EMT transcription factors is
not always observed [40, 45, 56]. Consistent with this, our study did not find any association
between the expression of CDH1 and the transcription factors despite the fact that CDH1 was
observed to be down-regulated in the majority (64.9%) of OSCC specimens. In addition to
being repressed by EMT-related proteins, CDH1 expression can be modulated by several other
mechanism including genomic deletion, loss of heterozygosity and promoter hypermethylation
[45, 57, 58], possibly explaining mechanisms of CDH1 down-regulation observed in this study.
Next, we examined the correlation between the expressions of these proteins with clinico-
pathological parameters, which could provide clues on the role of each protein, and could iden-
tify useful biomarkers for prognostication. In this study, we found that diffused LAMC2 was
associated with non-cohesive pattern of invasion while CDH1 loss was trending towards non-
cohesive pattern of invasion at the OSCC invasive front. This observation is consistent with
previous studies that showed that LAMC2 overexpression and CDH1 loss were also observed
in infiltrative strands or small nests of tumor cells and tumor buds in oral and pancreatic can-
cers [7, 16, 18, 23, 59] suggesting that LAMC2 and CDH1 proteins could participate in a phe-
nomenon known as tumor budding which is important for the ability of tumor cells to migrate
and invade [16, 48]. In addition, reduced CDH1 was also significantly observed in less differen-
tiated OSCC. This is perhaps not unexpected as CDH1 has an important role in maintaining
the structural and functional integrity of epithelium and upon the loss of CDH1, epithelial cell
polarity and cell adhesion are lost [30], giving rise to a phenotype that is frequently observed in
cells that are invading [30]. Interestingly, we did not see an association between the expression
of several EMT-related proteins and lymph node metastasis. While SNAI1/2 overexpression in
different tumors (head and neck, lung, pancreas, breast) were significantly associated with
node metastasis [15, 34, 40, 42, 44, 60], other studies showed no association [46, 61, 62]. Simi-
larly, the association between CDH1 loss and node metastasis is still inconclusive, whether
Table 4. (A) Cox regression analysis demonstrates that co-expression of TWIST1 and ZEB2 is an
independent prognostic factor for poor overall survival. (B) Cox regression analysis among patients with
negative cervical node demonstrates that co-expression of TWIST1 and ZEB2 is an independent prognostic
factor for poor overall survival.
A
Parameters Hazard Ratio (95% CI) p-value
TWIST1 and ZEB2 (No co-expression vs. Co-expression) 3.062 (1.314–7.138) 0.010*
TNM Stage (Early vs. Advance) 1.445 (0.459–4.544) 0.529
Lymph node metastasis (Negative vs. Positive) 2.271 (0.856–6.027) 0.100
Pattern of invasion (Cohesive vs. Non-Cohesive) 2.122 (0.632–7.129) 0.224
B
Parameters Hazard Ratio (95% CI) p-value
TWIST1 and ZEB2 (No co-expression vs. Co-expression) 3.765 (1.070–13.247) 0.039*
TNM Stage (Early vs. Advance) 1.198 (0.351–4.085) 0.772
Pattern of invasion (Cohesive vs. Non-Cohesive) 2.598 (0.717–9.416) 0.146
Abbreviations: CI, conﬁdence intervals
*p < 0.05.
doi:10.1371/journal.pone.0134045.t004
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these contradictory findings are associated with etiological factors remains to be examined [12,
20, 23, 63].
The occurrence of EMT has been shown to indicate an aggressive disease and therefore, we
hypothesized that expression patterns of EMT-related proteins could be associated with worse
prognosis in our OSCC patient cohort. Indeed, we observed a trend where TWIST1 and ZEB2
were associated with poor prognosis, although this did not reach statistical significance. As the
EMT process is complex and often involves more than one EMT-related protein [2, 4, 50], it is
likely that simultaneous overexpression of several EMT-related proteins are necessary for
tumorigenesis. Taking into the account the co-expression of TWIST1 and ZEB2, we found that
patients with expression of both proteins had significantly poorer survival compared to those
whose tumor only expressed one or none of the 2 proteins. This effect was more apparent
when we examined the expression of these 2 proteins amongst lymph node negative patients
where individuals with co-expression of TWIST1 and ZEB2 are 3.8 times more likely to have a
poor prognosis compared to those with the expression of either one or neither of the proteins
indicating that the co-expression of these 2 markers is an independent prognostic factor for
identifying aggressive disease particularly amongst lymph node negative patients. Emerging
evidence suggest that EMT-related markers have other oncogenic roles in addition to driving
the EMT process as measured by change of cell morphology and invasion. Although studying
the functional role of EMT proteins is not within the scope of this study, previous studies dem-
onstrated that TWIST1 and ZEB2 have other roles including repressing cellular senescence
and conferring stem-like properties to cancer cells respectively [64, 65].
Currently, histopathological assessment of surgical specimens according to the American
Joint Committee on Cancer and Union for International Cancer Control (AJCC and UICC)
staging criteria remains the gold standard in determining the extent of the disease, and contin-
ues to provide crucial information in determining the prognosis of the patient for treatment
planning. However, it is well accepted that patients with the same disease stage do not response
uniformly to similar treatment strategies and this is in part due to the inherent genetic drivers
that are unique to each tumor [66, 67]. While lymph node metastasis remains the most relevant
clinical prognosticator, the need to identify appropriate management for high risk individuals
with no detectable lymph node metastasis at the point of diagnosis is important [52]. There-
fore, the co-expression of TWIST1 and ZEB2 could be particularly important in identifying
patients without detectable regional metastasis but nevertheless should be treated aggressively.
Notably, both expressions of TWIST1 and ZEB2 have been reported to be of significant prog-
nostic value in early stage colorectal and oral cancer patients where disease spread is not always
evident [68, 69]. The mechanism by which this segregation happens is still unclear and further
investigation is needed, but perhaps, co-expression of TWIST1 and ZEB2 could identify
patients with undetected tumor spread. These observations will require further validation in an
independent cohort of patient specimens to ensure its robust use in the clinical setting.
In summary, following closely to the REMARK criteria [70], we report that EMT-related
markers are frequently differentially expressed between OSCC and NOM tissues. Consistent
with their known function, expression of some of these proteins were associated with clinico-
pathological phenotypes. Notably, co-expression of TWIST1 and ZEB2 was significantly preva-
lent in OSCC patients with poorer overall survival particularly in patients with no lymph node
metastasis. Further prospective studies focusing on these two transcription factors should be
able to determine their clinical value in identifying patients with poor survival for appropriate
management.
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S1 Fig. Representative immune-staining of EMT-related proteins in different cancers as
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400X).
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